Vanda Pharmaceuticals, Inc. (VNDA)
5.43
+0.09
(+1.69%)
USD |
NASDAQ |
Sep 04, 16:00
5.43
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Gross Profit Margin (Quarterly) : 89.02% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 89.02% |
| March 31, 2026 | 90.05% |
| December 31, 2025 | 86.65% |
| September 30, 2025 | 91.64% |
| June 30, 2025 | 91.47% |
| March 31, 2025 | 89.46% |
| December 31, 2024 | 91.84% |
| September 30, 2024 | 90.97% |
| June 30, 2024 | 91.11% |
| March 31, 2024 | 88.50% |
| December 31, 2023 | 90.25% |
| September 30, 2023 | 91.13% |
| June 30, 2023 | 91.58% |
| March 31, 2023 | 91.75% |
| December 31, 2022 | 89.74% |
| September 30, 2022 | 89.74% |
| June 30, 2022 | 90.00% |
| March 31, 2022 | 89.96% |
| December 31, 2021 | 90.29% |
| September 30, 2021 | 89.78% |
| June 30, 2021 | 89.79% |
| March 31, 2021 | 89.79% |
| December 31, 2020 | 89.98% |
| September 30, 2020 | 89.61% |
| June 30, 2020 | 90.01% |
| Date | Value |
|---|---|
| March 31, 2020 | 90.38% |
| December 31, 2019 | 89.18% |
| September 30, 2019 | 87.97% |
| June 30, 2019 | 88.58% |
| March 31, 2019 | 88.49% |
| December 31, 2018 | 88.60% |
| September 30, 2018 | 88.88% |
| June 30, 2018 | 88.15% |
| March 31, 2018 | 88.73% |
| December 31, 2017 | 88.20% |
| September 30, 2017 | 88.01% |
| June 30, 2017 | 88.20% |
| March 31, 2017 | 88.09% |
| December 31, 2016 | 80.71% |
| September 30, 2016 | 74.19% |
| June 30, 2016 | 73.81% |
| March 31, 2016 | 73.25% |
| December 31, 2015 | 71.38% |
| September 30, 2015 | 66.65% |
| June 30, 2015 | 68.43% |
| March 31, 2015 | 58.65% |
| December 31, 2014 | 91.20% |
| September 30, 2014 | 90.73% |
| June 30, 2014 | 91.22% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Protagonist Therapeutics, Inc. | 99.81% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Anika Therapeutics, Inc. | 65.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -77.19% |
| Return on Assets | -53.66% |
| Return on Invested Capital | -74.22% |
| Profit Margin (Quarterly) | -123.7% |
| Operating Margin (Quarterly) | -126.3% |
| Return on Net Operating Assets | -148.9% |